Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
1. ALLO-647 arm closed due to patient death from hepatic failure. 2. Standard FC lymphodepletion chosen for ALPHA3 study, simplifying treatment. 3. Encouraging MRD conversion rate reported, trial design remains unchanged. 4. Next futility analysis planned for 1H 2026. 5. Dagger® technology trials advancing without ALLO-647.